Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00456393 | Stomach | CAG | positive regulation of myeloid cell differentiation | 9/552 | 103/18723 | 3.40e-03 | 3.26e-02 | 9 |
GO:0045657 | Stomach | CAG | positive regulation of monocyte differentiation | 3/552 | 11/18723 | 3.52e-03 | 3.32e-02 | 3 |
GO:003166911 | Stomach | CAG | cellular response to nutrient levels | 14/552 | 215/18723 | 4.79e-03 | 4.18e-02 | 14 |
GO:00096122 | Stomach | CAG | response to mechanical stimulus | 14/552 | 216/18723 | 4.99e-03 | 4.26e-02 | 14 |
GO:00094104 | Stomach | WIM | response to xenobiotic stimulus | 33/426 | 462/18723 | 7.26e-09 | 1.20e-06 | 33 |
GO:004440341 | Stomach | WIM | biological process involved in symbiotic interaction | 25/426 | 290/18723 | 1.33e-08 | 1.82e-06 | 25 |
GO:001603241 | Stomach | WIM | viral process | 30/426 | 415/18723 | 2.74e-08 | 3.20e-06 | 30 |
GO:000697941 | Stomach | WIM | response to oxidative stress | 30/426 | 446/18723 | 1.34e-07 | 1.30e-05 | 30 |
GO:00316674 | Stomach | WIM | response to nutrient levels | 31/426 | 474/18723 | 1.54e-07 | 1.46e-05 | 31 |
GO:000030241 | Stomach | WIM | response to reactive oxygen species | 20/426 | 222/18723 | 1.88e-07 | 1.69e-05 | 20 |
GO:004254241 | Stomach | WIM | response to hydrogen peroxide | 16/426 | 146/18723 | 2.27e-07 | 1.96e-05 | 16 |
GO:006219741 | Stomach | WIM | cellular response to chemical stress | 25/426 | 337/18723 | 2.48e-07 | 2.09e-05 | 25 |
GO:003459941 | Stomach | WIM | cellular response to oxidative stress | 22/426 | 288/18723 | 8.05e-07 | 6.02e-05 | 22 |
GO:00436184 | Stomach | WIM | regulation of transcription from RNA polymerase II promoter in response to stress | 9/426 | 47/18723 | 9.51e-07 | 6.98e-05 | 9 |
GO:00022374 | Stomach | WIM | response to molecule of bacterial origin | 25/426 | 363/18723 | 9.89e-07 | 7.03e-05 | 25 |
GO:004362041 | Stomach | WIM | regulation of DNA-templated transcription in response to stress | 9/426 | 53/18723 | 2.74e-06 | 1.72e-04 | 9 |
GO:007099741 | Stomach | WIM | neuron death | 24/426 | 361/18723 | 3.01e-06 | 1.78e-04 | 24 |
GO:00972014 | Stomach | WIM | negative regulation of transcription from RNA polymerase II promoter in response to stress | 5/426 | 12/18723 | 4.13e-06 | 2.21e-04 | 5 |
GO:003461441 | Stomach | WIM | cellular response to reactive oxygen species | 14/426 | 155/18723 | 1.26e-05 | 5.63e-04 | 14 |
GO:00324964 | Stomach | WIM | response to lipopolysaccharide | 22/426 | 343/18723 | 1.37e-05 | 6.02e-04 | 22 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0493216 | Breast | Precancer | Non-alcoholic fatty liver disease | 48/684 | 155/8465 | 6.16e-17 | 1.50e-15 | 1.15e-15 | 48 |
hsa0513218 | Breast | Precancer | Salmonella infection | 49/684 | 249/8465 | 2.92e-09 | 6.15e-08 | 4.71e-08 | 49 |
hsa0513018 | Breast | Precancer | Pathogenic Escherichia coli infection | 38/684 | 197/8465 | 3.12e-07 | 5.81e-06 | 4.45e-06 | 38 |
hsa0513118 | Breast | Precancer | Shigellosis | 44/684 | 247/8465 | 3.91e-07 | 6.86e-06 | 5.26e-06 | 44 |
hsa0516718 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
hsa0491518 | Breast | Precancer | Estrogen signaling pathway | 28/684 | 138/8465 | 4.10e-06 | 5.39e-05 | 4.13e-05 | 28 |
hsa0541818 | Breast | Precancer | Fluid shear stress and atherosclerosis | 28/684 | 139/8465 | 4.74e-06 | 6.00e-05 | 4.59e-05 | 28 |
hsa0541718 | Breast | Precancer | Lipid and atherosclerosis | 37/684 | 215/8465 | 7.64e-06 | 9.29e-05 | 7.12e-05 | 37 |
hsa0516918 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa0465716 | Breast | Precancer | IL-17 signaling pathway | 20/684 | 94/8465 | 4.74e-05 | 4.54e-04 | 3.48e-04 | 20 |
hsa042108 | Breast | Precancer | Apoptosis | 25/684 | 136/8465 | 7.61e-05 | 6.87e-04 | 5.26e-04 | 25 |
hsa0516618 | Breast | Precancer | Human T-cell leukemia virus 1 infection | 33/684 | 222/8465 | 4.29e-04 | 3.31e-03 | 2.53e-03 | 33 |
hsa0413716 | Breast | Precancer | Mitophagy - animal | 15/684 | 72/8465 | 5.22e-04 | 3.93e-03 | 3.01e-03 | 15 |
hsa05031 | Breast | Precancer | Amphetamine addiction | 14/684 | 69/8465 | 1.05e-03 | 7.35e-03 | 5.63e-03 | 14 |
hsa052036 | Breast | Precancer | Viral carcinogenesis | 27/684 | 204/8465 | 7.19e-03 | 4.06e-02 | 3.11e-02 | 27 |
hsa0493217 | Breast | Precancer | Non-alcoholic fatty liver disease | 48/684 | 155/8465 | 6.16e-17 | 1.50e-15 | 1.15e-15 | 48 |
hsa0513219 | Breast | Precancer | Salmonella infection | 49/684 | 249/8465 | 2.92e-09 | 6.15e-08 | 4.71e-08 | 49 |
hsa0513019 | Breast | Precancer | Pathogenic Escherichia coli infection | 38/684 | 197/8465 | 3.12e-07 | 5.81e-06 | 4.45e-06 | 38 |
hsa0513119 | Breast | Precancer | Shigellosis | 44/684 | 247/8465 | 3.91e-07 | 6.86e-06 | 5.26e-06 | 44 |
hsa0516719 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
JUN | MLUM | Breast | DCIS | DUSP1,JUNB,MALAT1, etc. | 6.42e-01 | |
JUN | CD4TN | Cervix | CC | HSPA1B,DNAJB1,HSPA1A, etc. | 1.26e-01 | |
JUN | CD8TEFF | Cervix | CC | HSPA1B,DNAJB1,HSPA1A, etc. | 8.34e-02 | |
JUN | TFH | Cervix | CC | HSPA1B,DNAJB1,HSPA1A, etc. | 6.17e-02 | |
JUN | CD8TEXP | Liver | Cirrhotic | HSPA1A,HSPA1B,HSPB1, etc. | 1.35e-01 | |
JUN | CD8TCM | Pancreas | PDAC | DNAJB1,HSPA1B,ID2, etc. | 2.45e-01 | |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3725 | JUN | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TUMOR SUPPRESSOR, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | DIPHENHYDRAMINE HYDROCHLORIDE | DIPHENHYDRAMINE HYDROCHLORIDE | |
3725 | JUN | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TUMOR SUPPRESSOR, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | COLCHICINE | COLCHICINE | |
3725 | JUN | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TUMOR SUPPRESSOR, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | CIPROFIBRATE | CIPROFIBRATE | 16680159 |
3725 | JUN | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TUMOR SUPPRESSOR, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | VINBLASTINE SULFATE | VINBLASTINE SULFATE | |
3725 | JUN | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TUMOR SUPPRESSOR, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | PATULIN | PATULIN | 16680159 |
3725 | JUN | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TUMOR SUPPRESSOR, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | ALPHA-DIFLUOROMETHYLORNITHINE | | 9950818 |
3725 | JUN | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TUMOR SUPPRESSOR, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | METHIMAZOLE | METHIMAZOLE | |
3725 | JUN | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TUMOR SUPPRESSOR, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | DFMO | | 9950818 |
3725 | JUN | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TUMOR SUPPRESSOR, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | 2-MERCAPTOPYRIMIDINE | 2-MERCAPTOPYRIMIDINE | |
3725 | JUN | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, TUMOR SUPPRESSOR, TRANSCRIPTION FACTOR COMPLEX, TRANSCRIPTION FACTOR BINDING | | SODIUM SELENITE | SODIUM SELENITE | |